Search

Your search keyword '"Sefton, John"' showing total 31 results
Start Over Author "Sefton, John"
31 results on '"Sefton, John"'

6. Tazarotene Cream for the Treatment of Facial Photodamage: A Multicenter, Investigator-Masked, Randomized, Vehicle-Controlled, Parallel Comparison of 0.01%, 0.025%, 0.05%, and 0.1% Tazarotene Creams With 0.05% Tretinoin Emollient Cream Applied Once Daily for 24 Weeks

Author

Kang, Sewon, Leyden, James J., Lowe, Nicholas J., Ortonne, Jean-Paul, Phillips, Tania J., Weinstein, Gerald D., Bhawan, Jag, Lew-Kaya, Deborah A., Matsumoto, Richard M., Sefton, John, Walker, Patricia S., and Gibson, John R.

Published
2001

8. Tazarotene Cream for the Treatment of Facial Photodamage. (Study)

Author

Kang, Sewon, Leyden, James J., Lowe, Nicholas J., Ortonne, Jean-Paul, Phillips, Tania J., Weinstein, Gerald D., Bhawan, Jag, Lew-Kaya, Deborah A., Matsumoto, Richard M., Sefton, John, Walker, Patricia S., and Gibson, John R.

Subjects
Health
Published
2001

17. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis

Author

Lebwohl, Mark G., primary, Breneman, Debra L., additional, Goffe, Bernard S., additional, Grossman, Jay R., additional, Ling, Mark R., additional, Milbauer, James, additional, Pincus, Stephanie H., additional, Sibbald, R.Gary, additional, Swinyer, Leonard J., additional, Weinstein, Gerald D., additional, Lew-Kaya, Deborah A., additional, Lue, John C., additional, Gibson, John R., additional, and Sefton, John, additional

Published
1998
Full Text
View/download PDF

18. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis

Author

Lebwohl, Mark, primary, Ast, Ernest, additional, Callen, Jeffrey P., additional, Cullen, Stanley I., additional, Hong, Steven R., additional, Kulp-Shorten, Carol L., additional, Lowe, Nicholas J., additional, Phillips, Tania J., additional, Rosen, Theodore, additional, Wolf, David I., additional, Quell, Janine M., additional, Sefton, John, additional, Lue, John C., additional, Gibson, John R., additional, and Chandraratna, Roshantha A.S., additional

Published
1998
Full Text
View/download PDF

19. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis

Author

Smith, Edgar B., Wiss, Karen, Hanifin, Jon M., Jordon, Robert E., Rapini, Ronald P., Lasser, Alan E., Kirschenbaum, M. Barry, Millikan, Larry E., Parish, Lawrence Charles, Rapaport, Marvin J., Roenigk, Henry, Jr., Zaias, Nardo, Dromgoole, Sydney H., Sefton, John, DeGryse, Ronald, and Killey, Frank P.

Subjects
Athlete's foot -- Drug therapy, Clotrimazole -- Evaluation, Antifungal agents -- Dosage and administration, Health
Abstract

The antifungal agent naftifine has been approved in the United States for twice daily treatment of fungal infections of the foot, skin, and other areas of the body. Studies in Europe showed that naftifine may also be effective in a once-daily regimen. The effectiveness of naftifine 1 percent cream applied once or twice daily was compared with twice-daily applications of clotrimazole 1 percent cream. The study involved 155 men and 55 women with tinea pedis, or fungal infection of the foot. Within six weeks, treatment success was achieved in 81 percent of patients receiving twice- daily naftifine compared with 58 percent of patients treated with twice-daily clotrimazole who responded to treatment. Once- or twice-daily naftifine was more effective in resolving symptoms, such as redness, cracking, and itching, than twice-daily clotrimazole. There were no differences in the effects of the different doses of naftifine. Once- and twice-daily naftifine was more effective than twice-daily clotrimazole in treating the hyperkeratotic plantar-type of tinea pedis. Treatment-associated side effects included blisters or increased scaling with once-daily naftifine; skin inflammation with naftifine twice-daily; and flaring of blisters with clotrimazole twice-daily. The success of antifungal treatment applied to the skin depends on both the effectiveness of the drug and the ability of the patient to comply with a drug regimen. The results show that the once-daily application of the antifungal agent naftifine is more effective than twice-daily treatment with the antifungal agent clotrimazole. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

20. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect

Author

Weinstein, Gerald D., primary, Krueger, Gerald G., additional, Lowe, Nicholas J., additional, Duvic, Madeleine, additional, Friedman, David J., additional, Jegasothy, Brian V., additional, Jorizzo, Joseph L., additional, Shmunes, Edward, additional, Tschen, Eduardo H., additional, Lew-Kaya, Deborah A., additional, Lue, John C., additional, Sefton, John, additional, Gibson, John R., additional, and Chandraratna, Roshantha A.S., additional

Published
1997
Full Text
View/download PDF

21. DEVELOPMENT OF RAR SUBTYPE SELECTIVE RETINOIDS FOR DERMATOLOGICAL DISEASES

Author

Chandraratna, Roshantha A.S., primary, Henry, Elizabeth, additional, Attard, John, additional, Gillett, Samuel J., additional, Song, Tae, additional, Garst, Michael E., additional, Nagpal, Sunil, additional, Athanikar, Jyoti, additional, Arefieg, Taghreed, additional, Gil, Daniel W., additional, Wheeler, Larry A., additional, Lew-Kaya, Deborah, additional, and Sefton, John, additional

Published
1995
Full Text
View/download PDF

23. Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis

Author

Smith, Edgar B., primary, Breneman, Debra L., additional, Griffith, Russell F., additional, Hebert, Adelaide A., additional, Hickman, Janet G., additional, Maloney, J. Michael, additional, Millikan, Larry E., additional, Sulica, Virginia I., additional, Dromgoole, Sydney H., additional, Sefton, John, additional, DeGryse, Ronald E., additional, and Killey, Frank P., additional

Published
1992
Full Text
View/download PDF

25. Pharmacokinetics of Tazarotene Cream 0.1% After a Single Dose and After Repeat Topical Applications at Clinical or Exaggerated Application Rates in Patients with Acne Vulgaris or Photodamaged Skin.

Author

Zhiling Yu, Sefton, John, Lew-Kaya, Deborah A., Walker, Patricia S., D-S, Diane, Yu, Dale, and Tang-Liu, Diane D-S.

Subjects
*RETINOIDS, *TRETINOIN, *ACNE, *SKIN disease treatment, *CLINICAL drug trials, *PHARMACOKINETICS, *THERAPEUTICS
Abstract

Objective: To evaluate the safety and pharmacokinetics of tazarotene cream 0.1% under standard (face only) or exaggerated (15% body surface area, including the face) application conditions after a single dose and after repeat topical applications once daily to patients with acne vulgaris or photodamaged skin. Methods: Two separate, randomised, single-centre, nonblinded, parallel-group pharmacokinetic studies were conducted. In one study, tazarotene cream 0.1% was applied either to the face of eight female patients with moderate acne or to 15% body surface area of ten female patients with severe acne. In the other study, tazarotene cream 0.1% was applied either to the face (six females, two males) or to 15% body surface area (8 females. 8 males) of patients with photodamaged skin. In both studies, tazarotene cream 0.1% was applied once daily (except on days 1 and 2) for 30 days. Blood was drawn for measurement of plasma concentrations of tazarotenic acid at defined time intervals after applicat ion of the cream. Plasma tazarotenic acid concentrations were determined by a validated gas chromatography-tandem mass spectrometry method with a lower limit of quantification of 0.005 μg/L. Results: At exaggerated application rates in patients with acne vulgaris, the maximum average peak concentration (C[submax]) and 24-hour area under the concentration-time curve (AUC) values of tazarotenic acid were (mean ± SD) 1.20 ± 0.41 μg/L (n = 10) and 17.0 ±6.1 μg · h/L (n = 10), respectively, and occurred on day 15. The single highest C[submax] was 1.91 μg/L. At standard application rates in patients with acne vulgaris, the maximum average C[submax] and AUC values of tazarotenic acid were 0.10 ± 0.06 μg/L (n = 8) and 1.54 ± 1.01 μg · h/L (n = 8), respectively, and occurred on day 15. At exaggerated application rates in patients with photodamaged skin, the maximum average C[submax] and AUC values of tazarotenic acid were (mean ± SD) 1.75 ± 0.53 μg/L (n = 16) and 23.8 ± 7.0 μg • h/L (n = 16), respectively, and occurred on day 22. The single highest C[submax] was 3.43 μg/L on day 29. At standard application rates in patients with photodamaged skin, the maximum average C[submax] and AUC values of tazarotenic acid were 0.236 ± 0.255 μg/L (n = 8) and 2.44 ± 1.38 μg · h/L (n = 8), respectively, and occurred on day 15. Gender had no influence on the systemic exposure of tazarotenic acid. The most common treatment-related adverse events were signs and symptoms of local irritation, of mild or moderate severity. Conclusions: The pharmacokinetics of tazarotene cream 0.1% in patients with acne vulgaris or photodamaged skin are similar. The maximum average plasma concentrations of tazarotenic acid after topical application of tazarotene cream 0.1% to the face were less than 0.25 μg/L. The maximum average plasma concentrations of tazarotenic acid following application to an exaggerated body surface area (15%) were less than 1.8 μg/L. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results